Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 8/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701317 | 0.90 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL16701320 | 0.90 | CALML3 (0.49) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL1036062 | 0.87 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL13151038 | 0.87 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL1034941 | 0.87 | CALML3 (0.47) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537758 | 0.85 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537751 | 0.85 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7544447 | 0.84 | CALML3 (0.45) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL7537986 | 0.84 | CALML3 (0.44) | CALML3CYP3A4CYP2D6MAOAMAOB | |
| SCHEMBL9823246 | 0.83 | ALDH1A1 (0.53) | CYP3A4CYP2D6CYP2C9ALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2008069619-A1 | NOVEL OXAZOLIDINONE DERIVATIVES, PROCESS FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LEGOCHEM BIOSCIENCE LTD. (KR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126415-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2409/4885CYP3A4 773/4885CYP2D6 329/4885 |
| US-20230219941-A1 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF | OXA1L, THPO, TBCD | CALML3 2394/4885CYP3A4 833/4885CYP2D6 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.